ArticleDermatology and therapy2026

Baricitinib Efficacy Through 4 Years in Responders and Safety up to 5 Years in Adults with Severe Alopecia Areata: Final Results from BRAVE-AA1 and BRAVE-AA2.

Ruth Ann Vleugels et al.PubMed ↗Publisher ↗

No numbers read from the abstract.